Literature DB >> 2410106

Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection.

M G Sarngadharan, F diMarzo Veronese, S Lee, R C Gallo.   

Abstract

A high correlation was found among antibodies to human T-cell leukemia virus type III (HTLV-III), acquired immunodeficiency syndrome, and acquired immunodeficiency syndrome-related complex. With the Western blot technique the antigens (shown as proteins with molecular weights given in thousands) in HTLV-III lysates recognized by positive sera have been identified as p120, p66, p51, p41, p31, p24, and p17. The most common reactivity was toward p41. Lectin fractionation identified p120 and p41 as glycoproteins. Studies using mouse monoclonal antibodies to the p24 proteins of HTLV-I, -II, and -III showed that HTLV-I and -II have common epitopes in p24 molecule, but these are not the cross-reactive epitopes present on HTLV-III p24.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2410106

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Comparison of immunoblots with neutralizing and complement fixing antibodies in experimental and natural cases of visna-maedi.

Authors:  E G Torfason; M Gudnadóttir; A Löve
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 2.  Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

3.  Characterization of monoclonal antibodies directed against distinct conserved epitopes of human immunodeficiency virus type 1 core proteins.

Authors:  M Tatsumi; C Devaux; F Kourilsky; J C Chermann
Journal:  Mol Cell Biochem       Date:  1990-08-10       Impact factor: 3.396

4.  Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection.

Authors:  J V Giorgi; P G Nishanian; I Schmid; L E Hultin; H L Cheng; R Detels
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

5.  Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.

Authors:  Y Sei; P H Tsang; J P Roboz; P S Sarin; J I Wallace; J G Bekesi
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

6.  Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression.

Authors:  J S McDougal; M S Kennedy; J K Nicholson; T J Spira; H W Jaffe; J E Kaplan; D B Fishbein; P O'Malley; C H Aloisio; C M Black
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

7.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.